The healthcare and pharmaceutical sector experienced a mix of clinical setbacks and expansion moves. While Ultragenyx and Novartis faced major Phase 3 trial failures for key drug candidates, Ionis Pharmaceuticals secured landmark FDA approval for its Alexander disease treatment. Meanwhile, dealmaking remained active as American Healthcare REIT executed a $696 million senior housing acquisition and Menarini secured European rights for a GLP-1 candidate.
01Market mover
Novartis Experimental Cardiovascular Drug Fails Pivotal Study
Pelacarsen's failure decouples Lp(a) reduction from actual risk reduction, invalidating the key biomarker hypothesis underpinning rival cardiovascular pipelines at Amgen and Eli Lilly.
Novartis announced Friday that its experimental cardiovascular drug pelacarsen failed to reduce the risk of cardiovascular death, heart attacks, or strokes compared to a placebo in the HORIZON trial, according to statnews.com. The drug was designed to target and lower levels of Lp(a), a lipid and protein combination that raises the likelihood of severe heart problems when present in elevated concentrations. This setback is a major blow to the Swiss drugmaker and to broader pharmaceutical efforts to treat that specific heart disease risk factor. Competitors like Amgen and Eli Lilly are also developing therapies to lower Lp(a) levels.
Cipla Partners with Qilu Pharma for US Launch of Keytruda Biosimilar
Cipla's commercialization rights for Qilu's pembrolizumab candidate position Indian generic makers to capture post-patent biologics market share through cross-border manufacturing alliances rather than in-house development.
Cipla subsidiary Invagen Pharmaceuticals has inked an exclusive licensing and supply agreement with China-based Qilu Pharmaceutical to bring QL2107, a to Merck cancer drug Keytruda, to the U.S. market. Under the partnership, Qilu will handle development, regulatory registration, manufacturing, and supply, while Cipla USA takes charge of commercialization. Merck is set to lose patent protection for Keytruda in 2028. QL2107 aims to offer patients a more affordable treatment once regulatory hurdles are cleared.
Ultragenyx Angelman syndrome drug fails late-stage trial
When placebo controls invalidate early rare-disease signals, commercial biotechs lose the primary pipeline bridge required to turn current ultra-rare revenues into company-wide profitability.
Ultragenyx lost almost half its value after an experimental Angelman syndrome treatment missed all primary and secondary endpoints in a late-stage trial. The drug, known as GTX-102 or apazunersen, showed no difference compared to control groups in the Aspire study, forcing the company to evaluate the program for potential termination. Ultragenyx now plans to implement significant expense reductions as it shifts its focus toward approved products and profitability in 2027. The failure erased the therapy's projected peak sales of $1.8 billion or more, leaving upcoming treatments like the Sanfilippo syndrome candidate UX111 with substantially lower peak estimates of $120 million to $240 million. Ionis Pharmaceuticals shares fell 4% in early trading following the news, as the setback cast a shadow over similar antisense therapies in development.
FDA Approves First Ever Treatment for Alexander Disease
Securing four distinct regulatory priority designations for a rare-disease oligonucleotide validates Ionis's targeted RNA-targeting model by guaranteeing market exclusivity alongside accelerated commercialization.
The US Food and Drug Administration approved Zanvastro injection as the first treatment for Alexander disease in pediatric and adult patients. Developed by Ionis Pharmaceuticals, the antisense oligonucleotide works by reducing the production of the abnormal glial fibrillary acidic protein that drives the rare neurological disorder. The agency evaluated in a clinical study of 49 patients aged two years and older, alongside an open-label substudy of four younger patients. Patients aged five years and older treated with the drug showed significantly better walking speed at 61 weeks compared to untreated controls. The approval was granted after the therapy received orphan drug, fast track, breakthrough therapy, and rare pediatric disease designations.
Clinical Study Enrollment by Age Group (Patients)
The primary clinical study enrolled 49 patients, supplemented by 4 younger patients.
American Healthcare REIT Spends $696M on Senior Housing Acquisition
Shifting to new operator management agreements in high-income demographics allows the REIT to capture direct operational upside rather than relying solely on fixed triple-net lease rents.
American Healthcare spent $696 million to acquire eight senior housing communities spanning 867 units across six states. The transaction forms part of a broader $1.5 billion buying spree by the Irvine-based real estate investment trust, which also includes an 873 million dollar deal with Kensington Senior Living. The newly acquired properties, built between 2020 and 2022, are concentrated in affluent markets throughout Massachusetts, Connecticut, New Jersey, Pennsylvania, Delaware, and Georgia. American Healthcare REIT funded the expansion while establishing a new operating relationship with Norwood-based LCB Senior Living to manage the Northeastern properties. The company also appointed Aric Chang as its new chief financial officer, replacing Brian Paey effective October 1.
Senior Housing Portfolio Acquisitions ($M)
The REIT deployed over $1.5 billion across two major senior housing portfolios.
AbbVie Announces Phase 3 Win for Multiple Myeloma Drug Etentamig
Translating etentamig's progression-free survival benefit into global regulatory approvals would give AbbVie a targeted oncology therapy capable of offsetting patent cliff revenue losses in immunology.
AbbVie reported that its multiple myeloma drug etentamig cut the risk of disease progression or death by 60% compared to standard therapies in a . The randomized study, named Cervino, evaluated 393 patients with relapsed or refractory multiple myeloma who had received at least two prior lines of therapy. Patients treated with monthly intravenous etentamig achieved a 74% objective response rate, compared with 45.7% for the control arm receiving standard available therapies. The 12-month overall survival rate reached 87.9% for the drug group against 72% for standard care, though the prespecified boundary for overall survival had not been crossed at the data cutoff. Etentamig also demonstrated a manageable safety profile with a 28.3% incidence of mostly low-grade cytokine release syndrome. Following the positive interim analysis from the independent data monitoring committee, AbbVie plans to present the full findings at the International Myeloma Society Annual Meeting and discuss regulatory next steps with global authorities.
Cervino Trial Response and Survival Rates (%)
Etentamig significantly outperformed standard therapies across response and survival metrics.
Menarini Inks $771M Deal with Gan & Lee for European GLP-1 Rights
Menarini risks commercialization capital on an every-two-weeks dosing regimen to challenge incumbent once-weekly GLP-1 therapies in Europe by offering superior patient compliance.
Menarini Group agreed to pay Gan & Lee Pharmaceuticals €62 million up front for the European commercialization rights to the candidate bofanglutide. The agreement includes milestone payments of up to €664 million, alongside double-digit royalties on future sales. Menarini assumes responsibility for regulatory submissions and commercialization across 39 countries, covering the 27 European Union member states, the U.K., Switzerland, Norway, Iceland, Liechtenstein, and the Balkans. Bofanglutide requires subcutaneous administration once every two weeks, presenting a less frequent dosing schedule than existing once-weekly treatments in the class. Gan & Lee will initiate a global to support regulatory filings in Europe and other highly regulated markets.
Major Phase 3 trial failures offset breakthroughs like the first Alexander disease approval, while heavy M&A and licensing deals show capital flows remain strong. Whether recent clinical setbacks will suppress biotech valuations through the next quarter unresolved.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.